To the Editor.—
Drs Wilkerson and Wilkin have again introduced an atmosphere of ambiguity into the safety of DNCB therapy that ill serves the dermatologic community. In our article in the Archives, we concluded that it would be imprudent to continue the use of DNCB for the treatment of benign skin disorders.1 A portion of their letter suggests that they are in agreement, ie, they cite their previous work, which "broadly argued against the use of all current commercially available sources of DNCB."2 Whereas this certainly appears to complement our position, their "Wrong Tests, Wrong Conclusions" communication promulgates a circuitous logic that contradicts not only our conclusions but also what they claim to be their own. Thus, attention to several of their criticisms is warranted.First, Wilkerson and colleagues2,3 hypothesized that mononitrochlorobenzenes are responsible for conveying mutagenic properties to DNCB samples. We would point out that we
Black HS, Castrow FF. Oz Revisited. Arch Dermatol. 1986;122(1):15. doi:10.1001/archderm.1986.01660130017006
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: